These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37227016)

  • 21. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoledronic acid and atrial fibrillation in cancer patients.
    Arslan C; Aksoy S; Dizdar O; Dede DS; Harputluoglu H; Altundag K
    Support Care Cancer; 2011 Mar; 19(3):425-30. PubMed ID: 20358384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
    Nasomyont N; Hornung LN; Gordon CM; Wasserman H
    Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
    Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
    Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Zoledronic Acid in the Treatment of Osteoporosis.
    Hsieh PC
    Orthopedics; 2016; 39(2):e263-70. PubMed ID: 26881461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
    Sheedy KC; Camara MI; Camacho PM
    Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
    Yazici O; Aksoy S; Ucar O; Ozdemir N; Demir M; Sendur MA; Arik Z; Yaman S; Eren T; Uncu D; Zengin N
    Med Oncol; 2013; 30(3):609. PubMed ID: 23690271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients.
    Ding Q; Chen J; Fan J; Li Q; Yin G; Yu L
    Eur Spine J; 2017 Nov; 26(11):2969-2977. PubMed ID: 28865035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature.
    Nurmi-Lüthje I; Lüthje P
    J Med Case Rep; 2022 Dec; 16(1):473. PubMed ID: 36522673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
    Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
    Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
    BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers of inflammation after zoledronic acid redosing.
    Sykiotis A; Papaioannou G; Mavropoulos J; Triantaphyllopoulou M; Papandroulaki F; Ktena V; Thanou S; Pardalakis A; Kaltsa A; Karga H
    J Bone Miner Metab; 2014 Jan; 32(1):72-7. PubMed ID: 23690161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
    Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
    J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
    N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
    Li YF; Zhou CC; Li JH; Luo E; Zhu SS; Feng G; Hu J
    Osteoporos Int; 2012 Apr; 23(4):1463-74. PubMed ID: 21892678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Annual Injection of Zoledronic Acid Improves Bone Status in Children with Cerebral Palsy and Rett Syndrome.
    Wiedemann A; Renard E; Hernandez M; Dousset B; Brezin F; Lambert L; Weryha G; Feillet F
    Calcif Tissue Int; 2019 Apr; 104(4):355-363. PubMed ID: 30554334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.